- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03109652
Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients
Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients: A Randomized Controlled Study
Studieöversikt
Detaljerad beskrivning
It has been demonstrated that tranexamic acid (TXA) reduces the peri-operative blood loss as well as the need for transfusion in total knee replacement arthroplasty(TKRA). The anti-fibrinolytic effects of TXA have been shown to mainly present in the wound that, in previous studies, the use of TXA decreased the blood loss without increasing the risk of thromboembolic complications. Nevertheless, the optimal dose, duration of treatment and route of administration of TXA to reduce blood loss while minimizing adverse effects remain uncertain.
To use TXA as a pharmacologic alternative to transfusion, optimal regimen should be elucidated. Various studies have reported the effect of perioperative use of intravenous or topical TXA. Meta-analyses concluded that combined use of intravenous and topical TXA is more effective in reducing the blood loss and transfusion rate without increasing the risk of deep vein thrombosis or pulmonary embolism compared to the use of either intravenous TXA or topical TXA alone. Both intravenous and topical administration was conducted pre or intraoperatively or within 6 hours post-operatively mainly due to conceivable risk of thromboembolic event when TXA is used continuously after surgery. However, regarding the fact that systemic activation of fibrinolysis starts post-operatively in TKRA using tourniquets and lasts over 18 hours, the continuous use of TXA after surgery might have additional benefit over the single day use. Moreover, the serial use of post-operative oral TXA for 5 days after perioperative IV TXA use has been shown to significantly reduce transfusion rate without increasing thromboembolic complications compared to placebo.
Therefore, in this study, the investigators aimed to 1) investigate the effect of serial use of perioperative IV and post-operative oral TXA in reducing the blood loss and transfusion risk compared to single day perioperative use of IV TXA and 2) assess the sufficient length of postoperative use of oral TXA in TKRA patients.
Studietyp
Inskrivning (Förväntat)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
Dongjak Gu
-
Seoul, Dongjak Gu, Korea, Republiken av, 07061
- Rekrytering
- Seoul National University Boramae Medical Center
-
Kontakt:
- Seung-Baik Kang, MD, PhD
- Telefonnummer: +82-2-870-3931
- E-post: ossbkang@gmail.com
-
Kontakt:
- Chan Yoon, MD
- Telefonnummer: +82-2-870-2316
- E-post: yoon.chan.alex@gmail.com
-
Huvudutredare:
- Seung-Baik Kang, MD, PhD
-
Huvudutredare:
- Chong Bum Chang, MD, PhD
-
Huvudutredare:
- Moon Jong Chang, MD, PhD
-
Huvudutredare:
- Chan Yoon, MD
-
Huvudutredare:
- Min Kyu Song, MD
-
Huvudutredare:
- Jae-Hoon Shin, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Candidate for total knee replacement arthroplasty due to osteoarthritis of the knee.
Exclusion Criteria:
- Known allergic reaction to tranexamic acid
- Secondary arthritis (ex. Rheumatic arthritis, traumatic arthritis, septic arthritis)
- History of thromboembolic event including deep vein thrombosis, pulmonary embolism, cerebral infarction, transient ischemic attack, myocardial infarction, angina
- Premenopausal female
- Known congenital or acquired coagulopathy
- Currently in treatment with Adenosine disphosphate receptor inhibitors, Vitamin K antagonist, Factor Xa inhibitor, Direct thrombin inhibitor or Heparin
- Aspirin administration within 5 days before operation
- Preoperative Prothrombin time(PT) international normalized ratio(INR) > 1.4
- Severe systemic comorbidities of American Society of Anesthesiology (ASA) grade 4 including heart failure, renal failure, hepatic failure, pulmonary disease and cancer
- Do not agree to participate in the study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: IV TXA alone
One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation).
Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation.
|
On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups.
Oral TXA is given from postoperative day 1 only to experimental groups.
Duration of oral TXA administration is different between two experimental groups.
(5 days in "IV TXA and Oral TXA 5 days group" and 2 days in "IV TXA and Oral TXA 2 days group")
|
Experimentell: IV TXA and Oral TXA 5 days
One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation. Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 5. |
On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups.
Oral TXA is given from postoperative day 1 only to experimental groups.
Duration of oral TXA administration is different between two experimental groups.
(5 days in "IV TXA and Oral TXA 5 days group" and 2 days in "IV TXA and Oral TXA 2 days group")
|
Experimentell: IV TXA and Oral TXA 2 days
One ampule of 500mg/ml tranexamic acid(TXA) inj is injected intravenously during operation after box cutting procedure(before tourniquet deflation). Additionally, 1 ampule of TXA is administrated 3 hours after first injection on the day of operation. Two 250mg capsules of oral TXA(Transamin Cap) is given three times a day, 30 minutes after each meal, from postoperative day 1 to day 2. |
On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups.
Oral TXA is given from postoperative day 1 only to experimental groups.
Duration of oral TXA administration is different between two experimental groups.
(5 days in "IV TXA and Oral TXA 5 days group" and 2 days in "IV TXA and Oral TXA 2 days group")
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Change from preoperative hemoglobin at day 2
Tidsram: Preop. day 1 to postop. day 2
|
Hemoglobin (g/dL)
|
Preop. day 1 to postop. day 2
|
Change from preoperative hemoglobin at day 6
Tidsram: Preop. day 1 to postop. day 6
|
Hemoglobin (g/dL)
|
Preop. day 1 to postop. day 6
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Transfusion rate and amount
Tidsram: Postoperative day 0 to day 6
|
transfusion trigger: packed red blood cell(RBC) 1 pack is given if Hb < 7 or 7 ≤ Hb< 8 with symptom of anemia
|
Postoperative day 0 to day 6
|
Complications
Tidsram: up to 6 week after operation
|
CT angiography on postoperative day 6 for evaluation of deep vein thrombosis, Pulmonary embolism, superficial or deep infection, and other complications are assessed clinically.
|
up to 6 week after operation
|
Calculated Blood loss
Tidsram: Postop. day 6
|
Based on predicted blood volume and hemoglobin balance
|
Postop. day 6
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Seung-Baik Kang, MD, PhD, SMG-SNU Boramae Medical Center
Publikationer och användbara länkar
Allmänna publikationer
- Charoencholvanich K, Siriwattanasakul P. Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial. Clin Orthop Relat Res. 2011 Oct;469(10):2874-80. doi: 10.1007/s11999-011-1874-2. Epub 2011 Apr 22.
- Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol. 1981;20(1):65-72. doi: 10.1007/BF00554669.
- Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J, Mason JM. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br. 2011 Dec;93(12):1577-85. doi: 10.1302/0301-620X.93B12.26989.
- Wang H, Shen B, Zeng Y. Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials. Knee. 2014 Dec;21(6):987-93. doi: 10.1016/j.knee.2014.09.010. Epub 2014 Oct 23.
- Wu Q, Zhang HA, Liu SL, Meng T, Zhou X, Wang P. Is tranexamic acid clinically effective and safe to prevent blood loss in total knee arthroplasty? A meta-analysis of 34 randomized controlled trials. Eur J Orthop Surg Traumatol. 2015 Apr;25(3):525-41. doi: 10.1007/s00590-014-1568-z. Epub 2014 Nov 28.
- Irwin A, Khan SK, Jameson SS, Tate RC, Copeland C, Reed MR. Oral versus intravenous tranexamic acid in enhanced-recovery primary total hip and knee replacement: results of 3000 procedures. Bone Joint J. 2013 Nov;95-B(11):1556-61. doi: 10.1302/0301-620X.95B11.31055.
- Lin C, Qi Y, Jie L, Li HB, Zhao XC, Qin L, Jiang XQ, Zhang ZH, Ma L. Is combined topical with intravenous tranexamic acid superior than topical, intravenous tranexamic acid alone and control groups for blood loss controlling after total knee arthroplasty: A meta-analysis. Medicine (Baltimore). 2016 Dec;95(51):e5344. doi: 10.1097/MD.0000000000005344. Erratum In: Medicine (Baltimore). 2017 Feb 17;96(7):e6208.
- Li JF, Li H, Zhao H, Wang J, Liu S, Song Y, Wu HF. Combined use of intravenous and topical versus intravenous tranexamic acid in primary total knee and hip arthroplasty: a meta-analysis of randomised controlled trials. J Orthop Surg Res. 2017 Feb 2;12(1):22. doi: 10.1186/s13018-017-0520-4.
- Cankaya D, Dasar U, Satilmis AB, Basaran SH, Akkaya M, Bozkurt M. The combined use of oral and topical tranexamic acid is a safe, efficient and low-cost method in reducing blood loss and transfusion rates in total knee arthroplasty. J Orthop Surg (Hong Kong). 2017 Jan;25(1):2309499016684725. doi: 10.1177/2309499016684725.
- Benoni G, Lethagen S, Fredin H. The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty. Thromb Res. 1997 Feb 1;85(3):195-206. doi: 10.1016/s0049-3848(97)00004-2. Erratum In: hromb Res 1997 Oct 15;88(2):251.
- Blanie A, Bellamy L, Rhayem Y, Flaujac C, Samama CM, Fontenay M, Rosencher N. Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. Thromb Res. 2013 Jan;131(1):e6-e11. doi: 10.1016/j.thromres.2012.11.006. Epub 2012 Nov 26.
- Reikeras O, Clementsen T. Time course of thrombosis and fibrinolysis in total knee arthroplasty with tourniquet application. Local versus systemic activations. J Thromb Thrombolysis. 2009 Nov;28(4):425-8. doi: 10.1007/s11239-008-0299-6. Epub 2008 Dec 6.
- Nielsen CS, Jans O, Orsnes T, Foss NB, Troelsen A, Husted H. Combined Intra-Articular and Intravenous Tranexamic Acid Reduces Blood Loss in Total Knee Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial. J Bone Joint Surg Am. 2016 May 18;98(10):835-41. doi: 10.2106/JBJS.15.00810.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SNUBMC_2017001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Knäartros
-
Smith & Nephew, Inc.AvslutadJourney II BCS Total Knee SystemFörenta staterna, Belgien, Nya Zeeland
-
Smith & Nephew, Inc.Nor Consult, LLCAvslutadJourney II XR Total Knee SystemFörenta staterna
-
Smith & Nephew, Inc.Nor ConsultAvslutadJourney II CR Total Knee SystemFörenta staterna
-
Central DuPage HospitalAvslutadTotalt knäbyte | Ersättning, Total Knee | Artroplastik, knäplastikFörenta staterna
-
Bispebjerg HospitalRekryteringJumper's Knee | Patellar tendinopatiDanmark
-
Universidad Nacional de CórdobaAvslutadJumper's Knee | Patellar tendinitArgentina
-
University of VirginiaAvslutadArtros | Tibial Femoral Knee ArtrosFörenta staterna
-
Cairo UniversityAktiv, inte rekryterande
-
Bispebjerg HospitalUniversity College Absalon; Danske FysioterapeuterAktiv, inte rekryterandeJumper's Knee | Patellar tendinopatiDanmark
-
Bispebjerg HospitalRekryteringTendinopati | Jumper's KneeDanmark
Kliniska prövningar på Tranexamic Acid
-
University of SaskatchewanRekryteringRotator Cuff Skador | Subacromial Impingement Syndrome | Rotator Cuff Revor | Subacromial ImpingementKanada
-
London School of Hygiene and Tropical MedicineBarts & The London NHS Trust; St George's University Hospitals NHS Foundation... och andra samarbetspartnersAvslutadTraumatisk blödningStorbritannien
-
OrthoCarolina Research Institute, Inc.Avslutad
-
Ultragenyx Pharmaceutical IncAvslutadHereditary Inclusion Body Myopathy (HIBM)Förenta staterna
-
National University of Ireland, Galway, IrelandStanley Medical Research InstituteAvslutadBipolär depressionIrland
-
University of California, Los AngelesAvslutadGlukosintolerans | Fet | Pre-diabetesFörenta staterna
-
Becton, Dickinson and CompanyAktiv, inte rekryterande
-
Ultragenyx Pharmaceutical IncAvslutadÄrftlig inklusionskroppsmyopati | GNE Myopati | Inklusionskroppsmyopati 2 | Distal Myopati Med Kantade Vakuoler | Distal myopati, typ Nonaka | Quadriceps sparande myopatiKanada, Förenta staterna, Bulgarien
-
University of Colorado, DenverAvslutadFetma | Polycystiskt ovariesyndrom | Hepatisk SteatosFörenta staterna
-
University of VermontAvslutadTräningsinducerad fördröjd muskelömhetFörenta staterna